目的探讨经尿道膀胱电切术(transurethral resection of bladder,TURBt)同期进行尿道前列腺切除术(transurethral resection of prostate,TURP)治疗的浅表性膀胱癌合并良性前列腺增生(benign prostate hyperplasia,BPH)的临床效果。方...目的探讨经尿道膀胱电切术(transurethral resection of bladder,TURBt)同期进行尿道前列腺切除术(transurethral resection of prostate,TURP)治疗的浅表性膀胱癌合并良性前列腺增生(benign prostate hyperplasia,BPH)的临床效果。方法回顾性分析本院手术治疗的109例浅表性膀胱癌合并BPH患者的资料情况,其中采取TURBt同期行TURP治疗的患者57例(联合组)、仅采取TURBt资料52例(对照组),对比两组患者的手术效果就围手术期指标。结果联合组的手术时间、术中出血量、术后留置导尿管时间、术后住院时间均显著的长于对照组患者,且差异具有统计学意义(P<0.05);术后联合组的国际前列腺症状(international prostate symptom score,IPSS)评分、生存质量(quality of life score,QOL)评分、残余尿量(residual urine volume,PVR)测定值均显著的低于对照组患者(P<0.05),联合组的Qmax测定值显著地高于对照组患者(P<0.05);术后24个月,联合组和对照组的肿瘤复发率差异无统计学意义(P>0.05),联合组的尿道狭窄发生率(3.51%)显著低于对照组患者(17.31%),且差异具有统计学意义(P<0.05)。结论 TURBt同期TURP治疗的浅表性膀胱癌合并BPH虽然手术时间、出血量较多及术后恢复时间长较单纯TURBt,但是具有显著的改善患者术后排尿情况、生存质量及降低尿道狭窄发生率的作用。展开更多
Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in th...Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin （EPI）, pirarubicin （THP） and hydroxycamptothecin （HCPT） in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups （A and B） were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.展开更多
目的探讨浅表性膀胱癌患者经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor,TURBT)治疗的临床效果。方法选择2015年5月～2018年8月海南省第二人民医院诊治的74例浅表性膀胱癌患者为研究对象,将其随机分为观察组和对照组...目的探讨浅表性膀胱癌患者经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor,TURBT)治疗的临床效果。方法选择2015年5月～2018年8月海南省第二人民医院诊治的74例浅表性膀胱癌患者为研究对象,将其随机分为观察组和对照组,每组37例患者。观察组患者采用TURBT治疗,对照组患者采用膀胱部分切除术治疗,比较两组患者疗效、并发症发生和复发情况等。结果与对照组比较,观察组患者平均手术、膀胱冲洗、导尿留置和住院时间均显著缩短,术中失血量显著减少(t=18.066、13.880、7.623、7.564、12.560,均P<0.05);观察组和对照组患者治疗总有效率分别为83.8%、81.1%,其差异无统计学意义(χ~2=0.093,P>0.05);观察组患者并发症总发生率(8.1%)显著低于对照组患者(32.4%),其差异具有统计学意义(χ~2=6.772,P<0.05);观察组患者术后1、2年复发率(5.4%、16.2%)显著低于对照组患者(24.3%、37.8%),其差异具有统计学意义(χ~2=5.232、4.385,P<0.05);术后2年,观察组患者死亡率(0%)与对照组患者死亡率(8.1%)比较,其差异无统计学意义(χ~2=3.126,P>0.05);观察组患者治疗后SF-36量表总评分显著高于对照组患者,其差异具有统计学意义(t=15.028,P<0.05)。结论采用TURBT治疗浅表性膀胱癌患者,术后并发症发生和复发率均较低,可以使患者生活质量获得明显改善,远期疗效更为理想。展开更多
文摘目的探讨经尿道膀胱电切术(transurethral resection of bladder,TURBt)同期进行尿道前列腺切除术(transurethral resection of prostate,TURP)治疗的浅表性膀胱癌合并良性前列腺增生(benign prostate hyperplasia,BPH)的临床效果。方法回顾性分析本院手术治疗的109例浅表性膀胱癌合并BPH患者的资料情况,其中采取TURBt同期行TURP治疗的患者57例(联合组)、仅采取TURBt资料52例(对照组),对比两组患者的手术效果就围手术期指标。结果联合组的手术时间、术中出血量、术后留置导尿管时间、术后住院时间均显著的长于对照组患者,且差异具有统计学意义(P<0.05);术后联合组的国际前列腺症状(international prostate symptom score,IPSS)评分、生存质量(quality of life score,QOL)评分、残余尿量(residual urine volume,PVR)测定值均显著的低于对照组患者(P<0.05),联合组的Qmax测定值显著地高于对照组患者(P<0.05);术后24个月,联合组和对照组的肿瘤复发率差异无统计学意义(P>0.05),联合组的尿道狭窄发生率(3.51%)显著低于对照组患者(17.31%),且差异具有统计学意义(P<0.05)。结论 TURBt同期TURP治疗的浅表性膀胱癌合并BPH虽然手术时间、出血量较多及术后恢复时间长较单纯TURBt,但是具有显著的改善患者术后排尿情况、生存质量及降低尿道狭窄发生率的作用。
文摘Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin （EPI）, pirarubicin （THP） and hydroxycamptothecin （HCPT） in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups （A and B） were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.
文摘目的探讨浅表性膀胱癌患者经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor,TURBT)治疗的临床效果。方法选择2015年5月～2018年8月海南省第二人民医院诊治的74例浅表性膀胱癌患者为研究对象,将其随机分为观察组和对照组,每组37例患者。观察组患者采用TURBT治疗,对照组患者采用膀胱部分切除术治疗,比较两组患者疗效、并发症发生和复发情况等。结果与对照组比较,观察组患者平均手术、膀胱冲洗、导尿留置和住院时间均显著缩短,术中失血量显著减少(t=18.066、13.880、7.623、7.564、12.560,均P<0.05);观察组和对照组患者治疗总有效率分别为83.8%、81.1%,其差异无统计学意义(χ~2=0.093,P>0.05);观察组患者并发症总发生率(8.1%)显著低于对照组患者(32.4%),其差异具有统计学意义(χ~2=6.772,P<0.05);观察组患者术后1、2年复发率(5.4%、16.2%)显著低于对照组患者(24.3%、37.8%),其差异具有统计学意义(χ~2=5.232、4.385,P<0.05);术后2年,观察组患者死亡率(0%)与对照组患者死亡率(8.1%)比较,其差异无统计学意义(χ~2=3.126,P>0.05);观察组患者治疗后SF-36量表总评分显著高于对照组患者,其差异具有统计学意义(t=15.028,P<0.05)。结论采用TURBT治疗浅表性膀胱癌患者,术后并发症发生和复发率均较低,可以使患者生活质量获得明显改善,远期疗效更为理想。
